Skip to contentJune 2026
Phase 2a Non-Registrational Proof-of-Principle Trial of ERX1000 in Generalized Obesity Launched
October 2024
Phase 1 Dose Ranging and Safety Trial of ERX1000 Completed
April 2024
FDA Granted Orphan Drug Designation for ERX1000 for the Indication of Prader-Willi Syndrome
May 2019
First-in-Human Phase 1 Dose Ranging and Safety Trial of ERX1000 Completed
